A new weapon in the fight against children's brain tumors

March 2, 2016
To create the new mouse model of children's brain cancer, the researchers caused a mutation that occurs in many tumors, and used special stains to see the difference between healthy brain tissue (red) and the areas where the mutation took hold and a tumor arose (blue/green). Credit: University of Michigan

Children with brain cancer may soon get some help from mice with the same disease, thanks to new research from University of Michigan Medical School scientists and their colleagues.

In a new paper in Science Translational Medicine, the U-M team describes how they developed a novel brain tumor model in mice.

The mice have the same genetic problems as those seen in many children with the most dangerous forms of . That means the mice should be able to serve as a new test bed for treatments aimed at shrinking children's tumors.

Unlike adults with brain cancer, children cannot receive radiation therapy, so doctors must rely on medications and other strategies. Brain tumors are the leading cause of cancer death in children. A lack of treatment options keeps survival rates low.

"This is exciting because it's the first animal model of pediatric high-grade gliomas, or malignant ," says Maria Castro, Ph.D., senior author of the paper and a professor in the departments of Neurosurgery and Cell and Developmental Biology at U-M. "The mice carry the genetic mutations found in human tumors, and develop tumors that closely resemble what children and adolescents do."

And unlike previous attempts by others, the model generated at the U-M has a fully functional immune system, which makes it even more alike the children they mimic.

New research in mice could lead to better treatment for children with brain cancer, by providing a model for the disease and a testbed for treatments. Credit: University of Michigan

Brain cancer biology

In addition to developing the new genetically engineered mouse model for the form of cancer called glioblastoma multiforme, the researchers made a key discovery about brain tumor biology via the mice. Their work focuses on a protein called ATRX, and its role in helping cells repair damage to DNA. About one-third of children and young adults with brain cancer have ATRX mutations in their cancer cells.

Using a special genetic technique that introduced the same mutation in mice, soon after birth, the scientists were able to generate brain tumors that made less of the ATRX protein. Then, they showed that when the didn't make enough ATRX, the cells couldn't join together the two ends of a broken DNA strand.

This genetic instability accelerated tumor growth and reduced the survival of mice that went without treatment.

But in an ironic - and potentially beneficial - twist, the researchers also showed that if they treated the mice's tumors with drugs that damage DNA, they could actually shrink tumors more effectively and improve survival.

DNA-damaging cancer drugs already exist, and are used for other purposes in adults. If further research in the mice bears out, they could soon be tested in children whose brain tumors also show a decrease in ATRX production.

The first author of the study, U-M children's cancer specialist Carl Koschmann, M.D., helps guide the treatment of children with brain cancer at U-M's C.S. Mott Children's Hospital. He also studies brain cancer at the basic cell level in the Castro laboratory.

"We are very excited about this tumor model as it mimics the developmental environment of a pediatric or adolescent human brain tumor," he says. "We desperately need new therapies for pediatric GBM patients, as less than 20 percent of children diagnosed with GBM will survive five years. We currently base their treatment on a regimen designed for adult patients with GBM, which are very different tumors at the molecular level. Our mouse model has given us a great step towards developing targeted therapies to specific changes found in pediatric and adolescent GBM."

Accelerating discovery

Dr Castro's team at U-M, and their colleagues on teams at the Johns Hopkins School of Medicine, the University of Rochester, and the Institute of Cancer Research in London have been working toward this goal for several years.

A crucial aspect of the mouse model development was the ability to use what's called the "Sleeping Beauty" technique of inserting genes into stem cells in the brain of newborn . This allows their brain to develop normally, but also triggers the development of cancer by adding mutated ATRX genes and other genes known to be involved in cancer.

They also looked at genetic data on several hundreds of adult and from around the world. That helped them confirm that mutations in the gene that directs cells to make ATRX are responsible for making the tumors genetically unstable.

Personalizing treatment for brain tumors based on an individual's ATRX mutation status is still a concept, not a reality. But the researchers believe their mouse model and the close collaboration with pediatric brain cancer treatment teams at Mott Hospital will accelerate the ability to do so.

Explore further: Genetically engineered immune cell therapy found to boost survival in mice with brain tumors

More information: Science Translational Medicine (2016). DOI: 10.1126/scitranslmed.aac8228

Related Stories

Genetically engineered immune cell therapy found to boost survival in mice with brain tumors

February 24, 2016
Nagoya University-led research team shows in mice the potential of a special immune cell that targets a key protein in tumor growth that helps stop brain cancer.

Researchers find recurrent type of brain cancer tumor not a clone of the original

January 14, 2016
(Medical Xpress)—An international team of researchers has found evidence that shows that cancers that reoccur in patients with medulloblastomas are not necessarily derived from the same source as the original tumor. In ...

Study targets SGEF protein in treating glioblastoma brain tumors

January 13, 2016
The Translational Genomics Research Institute (TGen) has identified a protein called SGEF that promotes the survival of glioblastoma tumor cells and helps the cancer invade brain tissue.

Malignant brain tumors most common cause of cancer deaths in adolescents and young adults

February 24, 2016
A new report published in the journal Neuro-Oncology and funded by the American Brain Tumor Association (ABTA) finds that malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young ...

Removing all visible cancer is key to treating aggressive brain tumors

September 15, 2015
(HealthDay)—Surgery that removes all visible cancer significantly improves the chances of survival for children with aggressive brain tumors, especially girls.

Stem cells lurking in tumors can resist treatment

March 12, 2015
Scientists are eager to make use of stem cells' extraordinary power to transform into nearly any kind of cell, but that ability also is cause for concern in cancer treatment. Malignant tumors contain stem cells, prompting ...

Recommended for you

Insights on how SHARPIN promotes cancer progression

December 11, 2017
Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex ...

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

Glioblastoma survival mechanism reveals new therapeutic target

December 11, 2017
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation ...

Scientists discover possible master switch for programming cancer immunotherapy

December 11, 2017
During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells ...

Liver cancer: Lipid synthesis promotes tumor formation

December 11, 2017
Lipids comprise an optimal energy source and an important cell component. Researchers from the Biozentrum of the University of Basel and from the University of Geneva have now discovered that the protein mTOR stimulates the ...

Use of chemotherapy for early stage breast cancer declines, study says

December 11, 2017
A study of nearly 3,000 women with early stage breast cancer indicates a recent, significant decline in the use of chemotherapy despite the lack of any change in national treatment recommendations or guidelines, according ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.